Tularemia News and Research

RSS
Tularemia is a disease of animals and humans caused by the bacterium Francisella tularensis. Rabbits, hares, and rodents are especially susceptible and often die in large numbers during outbreaks. Humans can become infected through several routes, including tick and deer fly bites, skin contact with infected animals, ingestion of contaminated water, or inhalation of contaminated dusts or aerosols. In addition, humans could be exposed as a result of bioterrorism. Symptoms vary depending upon the route of infection. Although tularemia can be life-threatening, most infections can be treated successfully with antibiotics. Steps to prevent tularemia include use of insect repellent, wearing gloves when handling sick or dead animals, and not mowing over dead animals. In the United States, naturally occurring infections have been reported from all States except Hawaii.
ADLS receives $1.5M from exercise of unit warrants

ADLS receives $1.5M from exercise of unit warrants

Aradigm Corporation receives $891,000 to purchase common stock shares

Aradigm Corporation receives $891,000 to purchase common stock shares

Scientific update conference on Lyme and Tick-Borne Diseases

Scientific update conference on Lyme and Tick-Borne Diseases

Aradigm Corporation closes transaction with Novo Nordisk A/S

Aradigm Corporation closes transaction with Novo Nordisk A/S

Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress

Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

Advanced Life Sciences scientific publication demonstrates triterpenoids' potential as anticancer agents

BARDA awards $27 million contract to Achaogen for antibiotic development

BARDA awards $27 million contract to Achaogen for antibiotic development

Achaogen receives contract from BARDA for developing ACHN-490 antibiotic treatment

Achaogen receives contract from BARDA for developing ACHN-490 antibiotic treatment

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Aradigm reports net loss of $4.1M for second-quarter 2010

Aradigm reports net loss of $4.1M for second-quarter 2010

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences enters agreement with UBC to develop antimicrobial peptides

Advanced Life Sciences enters agreement with UBC to develop antimicrobial peptides

Advanced Life Sciences enters debt for equity exchange agreement with CEO

Advanced Life Sciences enters debt for equity exchange agreement with CEO

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences prices securities offering

Advanced Life Sciences prices securities offering

Aradigm announces $5 million private placement

Aradigm announces $5 million private placement

Immunosignature technique provides pre-symptomatic diagnosis for broad range of ailments

Immunosignature technique provides pre-symptomatic diagnosis for broad range of ailments

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's